Shares of Aspreva Pharmaceuticals Corp. sank to a new 52-week low on Wednesday after the company disclosed that the induction portion of a Phase III clinical trial of CellCept (oral mycophenolate mofetil) in lupus nephritis missed its primary endpoint. (BioWorld Today)